Agreement Supports on-going Development Programmes

Innova Biosciences, a specialist provider of bioconjugation products and services, has signed a licensing agreement which grants the use of its Lightning-Link^® and InnovaCoat^® GOLD technologies to be incorporated into Mologic’s commercial assay development services and range of immunoassays.

The deal provides Mologic with rights to incorporate Innova Technology into its products, including its full point of care diagnostic portfolio in addition to its B.I.T.S.™ range of high quality laboratory diagnostic assays.  The agreement also allows Mologic to provide customers with direct access to Innova’s leading technology when incorporated into product development programmes.

Dr Nick Gee, CEO of Innova Biosciences, commented: “We are delighted to sign this agreement with Mologic, which forms part of our strategy of working with high-quality partners. The Company has an excellent reputation in immunoassay development, and we see their decision to work with Lightning-Link and InnovaCoat GOLD as a powerful endorsement of our technologies.”

Mark Davis, CEO of Mologic, said: “We have already benefitted from using Innova’s conjugation technology and have seen excellent results across the product range.  The simplicity of Lightning-Link kits has led to them becoming essential tools for our highly efficient research group. Extending the relationship to a formal supply and licensing agreement will enable us to continue using the technologies in assay development, and as part of our custom services and disruptive product pipeline. We look forward to working with Innova further.”